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Summary A multivariate analysis of prognostic factors was carried out on 301 patients with clinical or
pathological stage III/IV Hodgkin's disease treated using the same combination chemotherapy (MVPP) at two
centres (Christie Hospital, Manchester, 151 patients, St. Bartholomew's Hospital, London, 150 patients).
There were no significant difference in CR or relapse free and overall survival at 5 and 10 years between the
two groups. Cox analysis of the Christie data alone produced four significant factors for survival - age, sex,
lymphocyte count and stage. The latter three factors showed the same trend for the St. Bartholomew's
Hospital patients but failed to reach statistical significance. Analysis of the combined data showed all four
factors to be of importance in predicting survival. Three different prognostic groups were identified which
separated patients with good, intermediate or poor prognosis in both centres. The good prognostic group
included patients aged <45 years, lymphocyte count >0.75 x1091-1 and female patients with stage IIIB
disease (5 year survival 85%). The rest were of poorer prognosis with male stage IV patients faring
particularly badly (5 year survival 40%).
Problems associated with the use of multivariate analysis to produce useful prognostic groupings in patients
from different centres, are discussed.
Chemotherapy (CT) has brought about a considerable
improvement in the survival of patients with advanced
Hodgkin's disease (HD). The combination CT regimens of
mustine, vincristine or vinblastine, procarbazine and predni-
solone (MOPP or MVPP) have been shown to produce
complete remissions (CR) in 71-77% of patients with 57-
66% of stage IIIB/IV patients remaining alive five years
from diagnosis (Sutcliffe et al., 1978; DeVita et al., 1980;
Bakemeier et al., 1984; Bonadonna et al., 1986; Wagstaff et
al., 1986). More intensive CT regimens may improve these
results with CR rates of 81-89% and five year survival rates
of 80-82% have recently been reported (Bonadonna et al.,
1986; Young et al., 1982; Klimo et al., 1985). However,
treatment related morbidity and mortality are considerable.
Actuarial estimates of the percentage of patients likely to
develop second cancers with such treatment are of the order
of 10% at 10 years, many of these being fatal (Coltman et
al., 1982; Glick et al., 1982; Tester et al.,1984; Dorreen et al.,
1986) and the majority of male patients are likely to be
permanently sterile (Cunningham et al., 1982).
Identification of pre-treatment characteristics predictive of
survival has been attempted in many diseases. One possible
use of such information would be to try and tailor treatment
to individual patients. This approach is important in
Hodgkin's disease, with its relatively high cure rates, where
the intensity of CT and radiotherapy (RT), can be altered to
increase the chances of cure, or to minimise the treatment
related morbidity and mortality. Initial attempts to identify
such factors were encouraging (Wagstaff et al., 1986). A
joint study between two different centres, in Manchester
(Christie Hospital) and London (St. Bartholomew's Hospital)
employing the same basic treatment regimen, was thus
initiated to confirm and expand these initial observations.
Patients and methods
Three hundred and one patients, 150 from St. Bartholo-
mew's Hospital (SBH) and 151 from the Christie Hospital,
with clinical or pathological stage IIIB or IV disease, are
included in the analysis. Pathology was reviewed at each
centre. Other entry criteria have been previously described
(Sutcliffe et al., 1978; Wagstaff et al., 1986), MVPP was the
treatment of choice at SBH, however, during the period
reported, 23/173 patients received ChlVPP or MVPP modifi-
cations when age or toxicity was felt to preclude administ-
ration of unmodified MVPP. At SBH, the intended number
of cycles for patients achieving complete remission (CR) was
6, although a small number of patients received maintenance
therapy for up to 4 years. At the Christie Hospital, it was
intended that patients should receive 6 cycles after apparent
clinical remission. A median of 7 cycles was given. Both
groups gave MVPP according to the dose and schedule
described by Nicholson et al., 1976. In both centres RT was
given if considered appropriate to sites of previous bulky
disease (any area measuring >5 cm or mediastinal width
greater than 1/3 transverse chest diameter at T5/6). CR was
defined as the complete disappearance of all evidence of
disease and the return to normal of all investigations which
had been abnormal as a consequence of HD before begin-
ning CT.
Survival was measured from the date of start of CT to the
date of death. Survival curves were based on the method of
Kaplan and Meier (1978), statistical significance being deter-
mined by the log rank test (Peto et al., 1977). For the
survival curves presented, patients were not censored for
deaths from causes other than HD. However analysis was
performed both with and without such censoring, and both
sets of results are presented in Table II.
The significance of the factors listed in Table I in deter-
mining the duration of survival was evaluated using a
stepwise linear regression method based on Cox's pro-
portional hazards model (Cox, 1972). The proportionality of
the hazards within each subdivision of these factors was
tested by stratifying for each factor in turn, and ensuring
that the remaining factors were unchanged in effect com-
pared with the overall model (Anderson, 1982). All the
factors were found to fit the model satisfactorily when
analysed in this fashion. This method was used on the two
data sets separately, and then on the two sets combined.
Factors significant at the 0.05% level were included. Conti-
nuous factors, such as age, were grouped categorically with
different cut-off points and compared with the results when
analysed continuously, in order to determine the best corre-
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lations. Having derived the relevant factors using the Cox
model in this fashion, survival curves were drawn for each
subgroup of the significant factors. This enabled sensible
prognostic groupings, based on the significance factors, to be
derived, rather than just using the regression coefficients
from the model. This method, as well as being clinically
more meaningful, avoids reliance on the additivity assump-
tion in the Cox model. This states that the effect of
prognostic factors on survival is additive for every value of
each variable, and was found not to be true for some of the
factors included in the analysis (see Results & Discussion).
Differences in patients characteristics between SBH and
the Christie Hospital were evaluated using the Mann-
Whitney U-test (MWU) for continuous variables, and the
chi-square test
variables.
with Yates correction for categorical
Table I Patient characteristics
Variable CategorY
All patients
Remission
Age
Sex
Stage
Bulk
Karnofsky performance score
Histology
Bone marrow involvement
Blood lymphocyte count ( x 1091 1
Haemoglobin
ESR (mmh-1)
Albumin
Alkaline phosphatase (IU l)
AST (IUl-1)
ALT (IUl-1)
Gamma GT (IU-11)
CR
<45
45-60
>60
male
female
IIIB
IVA
IVB
<Scm
>5cm
<70
80
90
missing
LP
NS
MC
LD
unclass.
absent
present
missing
<0.75
>0.75
missing
<13
>13
missing
<20
21-70
>70
missing
<33
>33
missing
<100
> 100
missing
<30
>30
missing
<40
>40
missing
<50
>50
missing
Manchester
no. (%)
151
101 (67)
109 (72)
27 (18)
15 (10)
100 (66)
51 (34)
38 (25)
24 (16)
89 (59)
79 (52)
69 (46)
52 (34)
48 (32)
46 (30)
5 (3)
14 (9)
47 (31)
78 (52)
12 (8)
0 (0)
120 (79)
17 (11)
14 (9)
42 (28)
107 (71)
2 (1)
114 (75)
37 (25)
0 (0)
28 (19)
57 (38)
51 (34)
15 (10)
32 (21)
119 (79)
0 (0)
46 (30)
102 (68)
3 (2)
101 (67)
49 (32)
1 (1)
82 (54)
13 (9)
56 (37)
55 (36)
50 (33)
46 (30)
Manchester
London vs. London
no. (%) p value
150
98 (65)
109 (73)
26 (17)
15 (10)
113 (75)
37 (25)
62 (41)
20 (13)
68 (45)
not recorded
not recorded
not recorded
not recorded
not recorded
not recorded
10 (7)
90 (60)
32 (21)
11 (7)
6 (5)
125 (83)
25 (17)
0 (0)
22 (15)
113 (75)
15 (10)
116 (77)
30 (20)
4 (3)
23 (15)
47 (31)
42 (28)
38 (25)
38 (25)
102 (68)
10 (7)
66 (44)
74 (49)
10 (7)
not recorded
not recorded
not recorded
not recorded
not recorded
not recorded
not recorded
not recorded
not recorded
NS
NS
NS
0.02
<<0.000 1
NS
0.03
NS
NS
NS
<0.001
Table II Significance of prognostic factors by treatment centre using the Cox model
Non-HD deaths Non-HD deaths
not censored censored
Factor Cutoff 2 P 2 p
1. Christie (Manchester) Age 45 and 60 23.8 <<0.0001 15.3 0.0001
Sex 13.7 0.0002 15.6 0.0001
Lymphocyte count 0.75 x 1091-1 13.0 0.0003 10.1 0.001
Stage IIIB 6.9 0.009 NS (0.06)
2. SBH (London) Age 45 11.6 0.0007 5.3 0.02
Histology LD and U 5.3 0.01 7.5 0.006
3. Christie & SBH Age 45 and 60 30.6 <<0.0001 17.2 0.0001
Sex 8.1 0.004 8.0 0.005
Lymphocyte count 0.75 x 1091 1 10.8 0.001 9.0 0.003
Stage IVA 6.7 0.009 7.7 0.005
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Remission duration Details of the characteristics of the two groups of patients
are given in Table I. All the factors listed were included in
n=199 the multivariate analysis. The main differences between the
two centres were in histology, with more mixed cellularity
(MC) as opposed to nodular sclerosing (NS) patients in the
n=301 Manchester group (P<0.0001), in lymphocyte count, with a
greater proportion of low counts in the Manchester group
(P=0.03), and in stage, with the Christie having more stage
IVB patients. The difference in serum alkaline phosphatase
(SAP) was probably due to the method of measurement, the
shape of distributions being similar in the two centres.
The CR rates were similar, 101/151 (67%) in Manchester,
3 6 9 12 15 18 and 98/150 (65%) in London. The survival curves for
Time (years) both groups were superimposable. The RFS curve for the Manchester patients was slightly above that for the London
1 The survival and remission duration of 301 patients patients but the difference was not significant (P=0.094).
tages IIIB and IV Hodgkin's disease treated with MVPP The overall survival and RFS curves for all patients are
therapy and radiotherapy to sites of bulky disease. shown in Figure 1. Cox analysis of the Christie data alone
produced four significant factors for survival, namely age,
sex, lymphocyte count and stage. Age was found to be
significant only above the age of 45 years after which
prognosis deteriorated rapidly. Age cut off points of 45 and
60 were thus used in the model. Age did not correlate with
34 prognosis in patients younger than 45. Lymphocytopenia
(<0.75 x 109 -1) correlated unfavourably with survival, as
did male sex and stage IV disease. Age was overwhelmingly
the most important factor, followed by sex and lymphocyte
count, with stage having much less effect (see Table II).
Using these tactors, survival curves were drawn for vari-
ous possible prognostic subgroups and three primary prog-
8 nostic categories were identified (see Figure 2). Of these three
groups, patients aged 45 years or younger, with a normal
lymphocyte count (52% of patients) had a good prognosis,
with a 5 year survival of 93%, irrespective of sex or stage.
Females with stage IIIB also had a good prognosis and are
2 4 6 8 10 12 included with this group. The remaining patients, with either
Time (years) a low lymphocyte count, or age >45 years had a much
2 The survival of patients with stages IIIB and IV worse survival, with females faring better than males in this
in's disease treated at the Christie divided by prognostic group. Older patients with few lymphocytes fared no worse
derived from a Cox analysis of the Christie data. than patients with just one of these poor prognostic factors.
Low risk - Age <45yrs with lymphocyte count Division of the SBH data by these Christie groupings shows
x 1091-1 (n=78) or female and stage IIIB (n=6). a similar set of curves although the advantage for females is
Intermediate risk - Female stage IV with age >45yrs or less marked (Figure 3).
ocyte count <0.75 x 1091-. Cox analysis of the SBH data identified two significant
High risk - Male with age > 45yrs or lymphocyte count factors, namely age and histology. Again, an age of greater
x 1091 1. than 45 years appeared to be the point at which prognosis
deteriorated. Patients with lymphocyte depleted HD, and
those with an unclassified histology, had a worse survival.
Although lymphocyte count was not significant in the Cox
analysis of the SBH data, this factor was highly correlated
with lymphocyte depleted histology in data from both
centres (P<0.001, chi-square test).
Using these two factors to draw survival curves for
possible prognostic subgroups two such groups were identi-
fied. Patients aged 45 years or greater, or those with
lymphocyte depleted or unclassified histology, had a much
worse survival than the rest (Figure 4). The SBH model
appears to fit the Christie data well (Figure 5). No addi-
tional statistical significance was gained by further subdivid-
ing the SBH data by age above and below 60, although the
curves for these two groups were similar to those from the
Christie Hospital. Analysis of the combined data identified
' a(t lusmnnhnout. t-rnnt ee-v aniA ctcaoP Ckc Qianrinnont fnotnrc
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Time (years) (see Table II). Neither lymphocyte count, sex nor stage
carried independent prognostic significance in the SBH data
3 The survival of patients with stages IIIB and IV but there were trends for all these factors to be correlated
in's disease treated at SBH divided by prognostic factors with survival. This, combined with the significance of these
i from a Cox analysis of the Christie data. factors in the Christie Hospital data was sufficient to bring
Low risk - Age <45yrs with lymphocyte count them into the combined model. When included in the
x 1091 1 (n = 78) or female and stage IIIB (n=6). regression centre itself was not sinificant confirming the
Intermediate risk - Female stage IV with age >45yrs or
s lgressaon, genthe got andS relts. ocyte count <0.75 x 1091- . similarity between the Christie Hospital and SBH results.
High risk - Male with age >45yrs or lymphocyte count Three different prognostic groups were identified for the
i x 1091- 1 combined data, the good prognosis category again being
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primarily related to age and lymphocyte count. Females with
stage IIIB also had a good prognosis. The remaining poor
prognosis patients with age >45 or lymphocyte count
<0.75x I091-1 could be further subdivided on sex and
stage, male patients with stage IV disease having a signifi-
cantly worse survival than the rest (P<0.001) (Table II and
Figure 6).
When survival times were censored for deaths from causes
other than HD, the significance of all factors remained very
similar, with the exception of age (Table II), where the
significance was considerably reduced in all the groups.
Discussion
Time
Figure 4 The survival of patier
Hodgkin's disease treated at SBH
derived from a Cox analysis of tl
(D) Low risk (SBH) - Age
sclerosing mixed cellularity or lyn
(E) High risk (SBH) - Age >
depleted or unclassified.
.0)
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9 12 15 18 A number of studies have looked in detail at prognostic
(years) factors for survival in advanced HD, several using multi-
nts with stages IIIB and IV variate methods (DeVita et al., 1980; Wagstaff et al., 1986;
divided by prognostic factors Rodgers et al., 1981; Peterson et al., 1982; Carde et al., 1983;
he SBH data. Pillai et al., 1985). A variety of significant factors have been
<45yrs or histology nodular reported, but the agreement between centres does not, on the
nphocyte predominant. surface, seem great. Considering only those centres perform-
45yrs or histology lymphocyte ing multivariate analyses, there appears to be some uniform-
ity of results, though the M.D. Anderson (MDA) identified
almost entirely different factors from all the rest. The MDA
apart, age was significant in all centres, while presence of
constitutional symptoms was significant in all but the
CALGB study (Rodgers et al., 1981). However, this latter
. n = 104 analysis included response as a factor. The two centres
(DeVita et al., 1980; Carde et al., 1983) who examined
pleural involvement found it significant, as did the two
centres (Peterson, 1982; Pillai et al., 1985) examining the
number of sites of extra-nodal disease. Only DeVita et al.
(1980) found histological subtype to be important, patients
E. = 47 with nodular sclerosing pathology having a significantly
shorter survival than the rest. However, a recent review of
these data (Kant et al., 1986; Longo et al., 1986) showed
histology to no longer be of independent prognostic signifi-
cance. Schilling et al. (1982) found serum LDH to be
2 4
Tim
Figure 5 The survival of patier
Hodgkin's disease treated at the
factors derived from a Cox analy
(D) Low risk (SBH) - Age
sclerosing mixed cellularity or lyn
(E) High risk (SBH) - Age >
depleted or unclassified.
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Figure 6 The survival of patier
Hodgkin's disease treated at SBI
prognostic factors derived from a
Christie data.
(A) Low risk - Age <45
>0.75 x 1091- or female and sta
(B) Intermediate risk- Rest.
(C) High risk - Male stage IV M
count <0.75x1091-1.
6 8 10 12 significant for survival, when allowing for age, stage, B
e (years) symptoms and histology, though this was not demonstrated in the Manchester analysis (Wagstaff et al., 1986). No other
nts with stages IIIB and IV studies have submitted this factor for multivariate analyses.
Christie divided by prognostic Turning to the studies employing univariate analyses,
rsis of the SBH data. Young et al., 1983, found lymphocytopenia (lymphocyte
<45yrs or histology nodular count <1 x 1091-1) at presentation to be a significant
nphocyte predominant.
45yrs or histology lymphocyte adverse predictor of survival, though Bjorkholm et al. (1982) did not. Neither performance status (Bakemeier et a., 1984;
Jones et al., 1982) nor stage (DeVita et al., 1980; Bakemeier
et al., 1984) have been of consistent significance in univariate
analysis. In most reports sex has not been an independent
prognostic factor, although Longo et al. (1986) found that it
contributed to the prediction of tumour related mortality
when considered in combination with clinical liver involve-
ment and pleural involvement. This factor was however
significant previously (Wagstaff et al., 1986) and again in the
combined SBH/Christie analysis.
Agreement in results between the two centres analysed in
this study was good. The main factor, namely age, predicted
survival equally well in both groups. Three other factors,
namely lymphocyte count, stage and sex were significant in
one group, and showed the same trend in the other group,
without reaching statistical significance. These factors may
merely be of less significance than age in which case this
9 12 15 18 finding is not unexpected, and may reflect slight differences
(years) in the patient populations. All three factors were significant
in the combined analysis. This magnitude of effect requires
ans with stages IIIB and IV relatively large numbers of patients to reach statistical
H and the Christie divided by significance, which may explain some of the discrepancies
noted between other studies. Although lymphocyte depleted
iyrs with lymphocyte count histology was significant in the SBH data alone, it was not
ge IIIB. significant in the combined data. This is because of its
correlation with lymphocyte count, with the two factors
vith age >45yrs or lymphocyte having similar prognostic relevance, though the latter shows
more significance.
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This agreement in results reported in this analysis was not
reached immediately. This was due to a number of problems
encountered in the multivariate analysis itself, and merits
further discussion. Although much effort has been devoted
to certain aspects of validation of the Cox multivariate
model approach (Anderson, 1986; Elashoff, 1983; Kay,
1983), other areas have been largely ignored. No criteria
have been established on how to treat individual variables
before inclusion in the model, making results difficult to
compare. For example, when a continuous variable such as
age is being analysed, should it be considered as having a
continuous effect on survival, or should it be divided into
subgroups, and if so, by what method? The approach taken
in this study has been to examine survival curves for the
continuous variables at several different cut-off points, in
order to allow understanding of the nature of the relation-
ship before inclusion in the model. The relationship between
lymphocytopenia and prognosis was initially unclear, and
others had used different divisions in their analyses (Young
et al., 1983). However, once a division above and below
0.75 x 1091-I was used, the results of the two centres were in
agreement. This division point showed the maximum effect
on survival, and delineated a relatively small bad prognosis
group of patients. The differences in significance for this
factor between the two centres appeared to be due to
differences in the proportions of patients with low counts,
not to differences in survival between patients with low as
compared to normal counts. Other problems with multi-
variate analysis include differences in patient populations
(for instance histological difference in this analysis) and
differences in the factors actually included for analysis.
When significant factors have been defined using multi-
variate analysis, further confusion may become apparent in
defining the different associated prognostic categories and
scoring systems. Common sense is required, since direct
application of the model can be misleading. The 'additivity'
of the factors, i.e. the assumption, implicit in the Cox model,
that the effect on survival of each of the factors is additive is
often seen to be invalid. One implication of this assumption
is that two bad prognostic factors are always considerably
worse than one. This is not always true, since a patient's
prognosis qan be determined by just one bad factor. Equally,
as can be seen in this study, once a patient is in the 'good'
prognosis group, having other 'good' prognostic factors will
not necessarily further increase his chances of survival.
All these difficulties make it easy to see why different
results are produced by different centres, but happily this
makes it particularly encouraging that agreement was found
between the two sets of data examined in this study. If the
patient populations, prognostic factors analysed, and group-
ings used in the analysis are all defined, it may, in the future,
be possible to show reproducibility between centres.
It is encouraging for the treatment of advanced HD that
two simple factors can be used to identify patients who are
likely to have prolonged survival. These patients form some
55% of the total population, and treatment is likely to be
very effective for this group, with a 10 year survival of 77%.
The remaining bad risk patients, especially those males with
stage IV disease, have a much greater mortality. For this
latter group, it may be necessary to use other alternative
forms of treatment.
This analysis does not include an analysis of factors
predicting for complete response or relapse free survival for
reasons of space, but factors affecting CR rate and duration
of remission have previously been published for the Christie
Hospital patients (Wagstaff et al., 1986).
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